Journey Medical Corp

DERM remains in early Stage 1 consolidation following a terminal decline and range-bound repair. A late-June breakout failed, evidenced by a Bullish Exhaustion candle, and price is overbought and facing resistance. This leads to a bearish medium-term bias, recommending selling into strength near the breakout region.

• ↑MROSI net sales hit $14.7M in first nine months; total revenues +11% YoY.
• ↑Gross margin expanded to 66.2% from 62.8% YoY, driven by favorable product mix.
• ↓Net loss of $11.4M in 2025 (vs. $14.7M prior year); EBITDA still negative.